230 related articles for article (PubMed ID: 37418574)
21. Association of Adjuvant Radiotherapy With Survival After Margin-negative Resection of Pancreatic Ductal Adenocarcinoma: A Propensity-matched National Cancer Database (NCDB) Analysis.
Kamarajah SK; Sonnenday CJ; Cho CS; Frankel TL; Bednar F; Lawrence TS; Nathan H
Ann Surg; 2021 Mar; 273(3):587-594. PubMed ID: 30817352
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of Adjuvant Chemotherapy in Patients With Resected Pancreatic Cancer After Neoadjuvant FOLFIRINOX Treatment.
van Roessel S; van Veldhuisen E; Klompmaker S; Janssen QP; Abu Hilal M; Alseidi A; Balduzzi A; Balzano G; Bassi C; Berrevoet F; Bonds M; Busch OR; Butturini G; Del Chiaro M; Conlon KC; Falconi M; Frigerio I; Fusai GK; Gagnière J; Griffin O; Hackert T; Halimi A; Klaiber U; Labori KJ; Malleo G; Marino MV; Mortensen MB; Nikov A; Lesurtel M; Keck T; Kleeff J; Pandé R; Pfeiffer P; Pietrasz D; Roberts KJ; Sa Cunha A; Salvia R; Strobel O; Tarvainen T; Bossuyt PM; van Laarhoven HWM; Wilmink JW; Groot Koerkamp B; Besselink MG;
JAMA Oncol; 2020 Nov; 6(11):1733-1740. PubMed ID: 32910170
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.
Adam MA; Nassour I; Hoehn R; Hlavin CA; Bahary N; Bartlett DL; Lee KKW; Zureikat AH; Paniccia A
Ann Surg Oncol; 2021 Jul; 28(7):3800-3807. PubMed ID: 33386547
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of Adjuvant Chemotherapy According to the Pathological Response to Neoadjuvant Chemotherapy Among Patients With Pancreatic Ductal Adenocarcinoma.
Mori S; Aoki T; Sakuraoka Y; Shimizu T; Yamaguchi T; Park KH; Matsumoto T; Shiraki T; Iso Y; Kubota K
Anticancer Res; 2021 Mar; 41(3):1629-1639. PubMed ID: 33788759
[TBL] [Abstract][Full Text] [Related]
25. Role of Surgery and Perioperative Therapy in Older Patients with Resectable Pancreatic Ductal Adenocarcinoma.
Xie H; Liu J; Yin J; Ogden JR; Mahipal A; McWilliams RR; Truty MJ; Bekaii-Saab TS; Petersen GM; Jatoi A; Hubbard JM; Ma WW
Oncologist; 2020 Nov; 25(11):e1681-e1690. PubMed ID: 32663355
[TBL] [Abstract][Full Text] [Related]
26. Survival benefit of surgery with postoperative radiotherapy in locally advanced cervical adenocarcinoma: a population-based analysis.
Wang X; Lu X; Chen J; Yi H; Lan Q
BMC Surg; 2023 Oct; 23(1):299. PubMed ID: 37789291
[TBL] [Abstract][Full Text] [Related]
27. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
[TBL] [Abstract][Full Text] [Related]
28. Impact of adjuvant chemotherapy after pancreaticoduodenectomy for distal cholangiocarcinoma: a propensity score analysis from a French multicentric cohort.
Bergeat D; Turrini O; Courtin-Tanguy L; Truant S; Darnis B; Delpero JR; Mabrut JY; Regenet N; Sulpice L
Langenbecks Arch Surg; 2018 Sep; 403(6):701-709. PubMed ID: 30112638
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
Setakornnukul J; Thephamongkhol K
BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
[TBL] [Abstract][Full Text] [Related]
30. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study.
Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP
Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211
[TBL] [Abstract][Full Text] [Related]
31. Neoadjuvant Radiotherapy After (m)FOLFIRINOX for Borderline Resectable Pancreatic Adenocarcinoma: A TAPS Consortium Study.
Janssen QP; van Dam JL; Prakash LR; Doppenberg D; Crane CH; van Eijck CHJ; Ellsworth SG; Jarnagin WR; O'Reilly EM; Paniccia A; Reyngold M; Besselink MG; Katz MHG; Tzeng CD; Zureikat AH; Groot Koerkamp B; Wei AC;
J Natl Compr Canc Netw; 2022 Jul; 20(7):783-791.e1. PubMed ID: 35830887
[TBL] [Abstract][Full Text] [Related]
32. Post-adjuvant chemotherapy CA19-9 levels predict prognosis in patients with pancreatic ductal adenocarcinoma: A retrospective cohort study.
Imaoka H; Shimizu Y; Senda Y; Natsume S; Mizuno N; Hara K; Hijioka S; Hieda N; Tajika M; Tanaka T; Ishihara M; Niwa Y; Yamao K
Pancreatology; 2016; 16(4):658-64. PubMed ID: 27178104
[TBL] [Abstract][Full Text] [Related]
33. Response to Neoadjuvant Therapy and Prognosis in Patients with Resectable Pancreatic Cancer: A Propensity Score Matching Analysis.
Yoon MS; Lee HS; Kang CM; Lee WJ; Keum J; Sung MJ; Kim SS; Park MS; Jo JH; Chung MJ; Park JY; Park SW; Song SY; Hwang HK; Bang S
Gut Liver; 2022 Jan; 16(1):118-128. PubMed ID: 34140428
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis.
Chen X; Liu G; Wang K; Chen G; Sun J
Oncotarget; 2017 Jul; 8(29):47831-47840. PubMed ID: 28599299
[TBL] [Abstract][Full Text] [Related]
35. Whether early stage pancreatic ductal adenocarcinoma patients could benefit from the post-operation chemotherapy regimens: a SEER-based propensity score matching study.
Shi J; Li X; Wu Y
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2021 Jun; 50(3):375-382. PubMed ID: 34402250
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant Chemotherapy vs Observation for Patients With Adverse Pathologic Features at Radical Cystectomy Previously Treated With Neoadjuvant Chemotherapy.
Seisen T; Jamzadeh A; Leow JJ; Rouprêt M; Cole AP; Lipsitz SR; Kibel AS; Nguyen PL; Sun M; Menon M; Bellmunt J; Choueiri TK; Trinh QD
JAMA Oncol; 2018 Feb; 4(2):225-229. PubMed ID: 28837718
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry.
Worni M; Akushevich I; Gloor B; Scarborough J; Chino JP; Jacobs DO; Hahn SM; Clary BM; Pietrobon R; Shah A
Ann Surg Oncol; 2012 Apr; 19(4):1316-23. PubMed ID: 22002799
[TBL] [Abstract][Full Text] [Related]
38. Oncologic impact of preoperative prognostic nutritional index change in resected pancreatic cancer following neoadjuvant chemotherapy.
Kim KH; Hwang HK; Kang IC; Lee WJ; Kang CM
Pancreatology; 2020 Mar; 20(2):247-253. PubMed ID: 31889624
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and Safety of Neoadjuvant Chemotherapy Combined with Adjuvant Chemotherapy for Locally Advanced Colon Cancer: A Propensity Score-Matching Analysis.
Zeng W; Liu Y; Wang C; Yang C; Lin S; Li W
Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363462
[TBL] [Abstract][Full Text] [Related]
40. Impact of S-1 adjuvant chemotherapy longer than 6 months on survival in patients with resected pancreatic cancer: a nationwide survey by the Japan Pancreas Society based on real-world data.
Tomimaru Y; Eguchi H; Inoue Y; Nagakawa Y; Ohba A; Takami H; Unno M; Yamamoto T; Kawakatsu S; Hayashi T; Higuchi R; Kitagawa H; Hattori S; Fujii T; Hirooka Y; Igarashi H; Kitano M; Kuroki T; Masamune A; Shimizu Y; Tani M; Tanno S; Tsuji Y; Yamaue H; Satoi S; Takeyama Y;
Cancer; 2023 Mar; 129(5):728-739. PubMed ID: 36504020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
